stockrowAurinia Pharmaceuticals Inc
AUPH Healthcare Biotechnology
Aurinia Pharmaceuticals Inc’s revenue for fiscal 2025 (year ended December 2025) was $283.1 million, up 20.4% from fiscal 2024.
- Revenue
- +13.9%
- EPS
- 0.00%
- Free cash flow
- +4.41%
- Total debt
- −30.0%
Quarter to September 2026, against a year earlier
Follow AUPH
Alert me
Aurinia Pharmaceuticals Inc (AUPH) Total debt
Aurinia Pharmaceuticals Inc's total debt at the end of fiscal 2025 was $52.3M, down 10.6% from $58.6M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $39.0M. Over the past ten years it has ranged from $5.3M (fiscal 2022) to $75.5M (fiscal 2023); the current reading is higher than 67% of that period. Aurinia Pharmaceuticals Inc ranks 141st of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $52.3M | (10.64%) |
| FY2024 | $58.6M | (22.42%) |
| FY2023 | $75.5M | 1,324.73% |
| FY2022 | $5.3M | (12.39%) |
| FY2021 | $6.0M | 0.80% |
| FY2020 | $6.0M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $39.0M | (11.18%) |
| Jun 2026 | $43.9M | (8.80%) |
| Mar 2026 | $48.2M | (7.91%) |
| Dec 2025 | $52.3M | (6.11%) |
| 26 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| BHVN Biohaven Ltd. compare | $264.3M |
| ADMA ADMA Biologics Inc compare | $198.9M |
| VCEL Vericel Corporation compare | $85.1M |
| VERA Vera Therapeutics, Inc. compare | $75.2M |
| AUPH Aurinia Pharmaceuticals Inc | $39.0M |
| PVLA Palvella Therapeutics, Inc. compare | $12.3M |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | $5.5M |
| CLDX Celldex Therapeutics, Inc. compare | $1.2M |
| IMNM Immunome, Inc. compare | $228.0K |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on AUPH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement